NDC codes

FDA NDC Directory
Product NDC (as listed)70756-809Labeler and product segments. Claims need a package NDC.
Product NDC at billing width70756-0809Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
70756-809-307075608093030 TABLET in 1 BOTTLE (70756-809-30)Marketed from May 1, 2020
70756-809-907075608099090 TABLET in 1 BOTTLE (70756-809-90)Marketed from May 1, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Olmesartan Medoxomil
Generic name (nonproprietary)
olmesartan medoxomil
Active ingredients
Olmesartan medoxomil — 20 mg/1
Dosage form
Tablet
Route
Oral
Product type
Prescription drug
Marketing category
ANDA — Abbreviated New Drug Application (generic)Application ANDA 207135
Marketing start
Listing expires
Other FDA classes
Angiotensin 2 Receptor Antagonists (Mechanism)
Identifiers
Product ID 70756-809_45810d23-5c40-8cba-e063-6294a90a8e9cSPL ID 45810d23-5c40-8cba-e063-6294a90a8e9cSPL set ID a337a621-bf57-4aa4-8224-4356fa2cdbc4RxCUI 349373, 349401, 349405UNII 6M97XTV3HD

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470756080930 followed by a unit qualifier and the quantity

Package 70756-0809-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective . This label includes a boxed warning.

Indications (excerpt from the label)

1. INDICATIONS AND USAGE Olmesartan medoxomil is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 207135

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 207135
ProductStrengthForm · routeLabelerProduct NDC
Olmesartan MedoxomilOlmesartan medoxomil 5 mg/1TabletOralLifestar Pharma LLC70756-808
Olmesartan MedoxomilOlmesartan medoxomil 40 mg/1TabletOralLifestar Pharma LLC70756-810
Olmesartan MedoxomilOlmesartan medoxomil 5 mg/1TabletOralUmedica Laboratories USA Inc.60290-009
Olmesartan MedoxomilOlmesartan medoxomil 20 mg/1TabletOralUmedica Laboratories USA Inc.60290-010
Olmesartan MedoxomilOlmesartan medoxomil 40 mg/1TabletOralUmedica Laboratories USA Inc.60290-011

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free Med-Code account to keep looking up NDCs, J-codes and drugs.

Create a free accountLog in